{"name":"Yan Zhang, MD","slug":"yan-zhang-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Polatuzumab Vedotin, Rituximab, Lenalidomide","genericName":"Polatuzumab Vedotin, Rituximab, Lenalidomide","slug":"polatuzumab-vedotin-rituximab-lenalidomide","indication":"Diffuse large B-cell lymphoma","status":"phase_2"}]}],"pipeline":[{"name":"Polatuzumab Vedotin, Rituximab, Lenalidomide","genericName":"Polatuzumab Vedotin, Rituximab, Lenalidomide","slug":"polatuzumab-vedotin-rituximab-lenalidomide","phase":"phase_2","mechanism":"Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor","indications":["Diffuse large B-cell lymphoma","Follicular lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE13bF9JelBLRGluWURTbEVHRzFDVF8xNDA3U2FpNUN3cmhoNTBhZk1ndWs0a2xpd2dOYWNCbkRiMlVpR1JFNC1yLVZwSXUzemlvNVFXQkVpT01UQVkyQkp3cVR4VmlVM0xmb2E0alBLbUM4X2txLWt5UA?oc=5","date":"2025-05-21","type":"pipeline","source":"ahajournals.org","summary":"Intracellular L-PGDS–Derived 15d-PGJ2 Inhibits CaMKII Through Lipoxidation to Alleviate Cardiac Ischemia/Reperfusion Injury | Circulation - ahajournals.org","headline":"Intracellular L-PGDS–Derived 15d-PGJ2 Inhibits CaMKII Through Lipoxidation to Alleviate Cardiac Ischemia/Reperfusion Inj","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9ZQzVMdlBXZmRYVERMTVJpTTFfRTVYa1FnZm9FYWdNc2xnT3VkYWxMUW53UEVZT01ZaTZzTkx4RVlTU2UtMlE0bDhZNzhmbGNTVlJNaFBfNHF0OERmUEZMUVQxalQ0c25FUnZrVWlvdGhpWjZQME43U0Jqaw?oc=5","date":"2025-01-02","type":"regulatory","source":"acsjournals.onlinelibrary.wiley.com","summary":"Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial - acsjournals.onlinelib","headline":"Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9KenQ0NGpWbHp3UEJKaURJMXQ2ZEtiSGtxazV0ekdKZmMwNXVsQkFBRThtS1pnUGFYcEx5TDZtbTRabm9tdTJDeUdrQlBLb3VDZlQ4eTRpUDNuVktjZUR6TWRhOEtNajBDYVBScUJMeTlmQQ?oc=5","date":"2024-12-20","type":"pipeline","source":"ahajournals.org","summary":"Large-Scale Plasma Proteomics Profiles for Predicting Ischemic Stroke Risk in the General Population - ahajournals.org","headline":"Large-Scale Plasma Proteomics Profiles for Predicting Ischemic Stroke Risk in the General Population","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE51bFRBYnV1aFNUQzVwX3duTnBNWGRFQ1JoTmoyWUZ4bkVvTGNHazN5VkdpRURnd1lMVHUxLWFRRHU1MlFfelJleXZKdHZlN052SzE3TnNQOEJvbVdDVFc3Qmo5Y3pjTWhTRFpiYzNoMUVkUzQ?oc=5","date":"2024-10-16","type":"pipeline","source":"ahajournals.org","summary":"Extracellular RIPK3 Acts as a Damage-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury - ahajournals.org","headline":"Extracellular RIPK3 Acts as a Damage-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE0xcjFhT2llTlJsWUJ4cUtfMEhTWi1xR2xjUG9acFgtNURwZEk4dEJ6MlVOUjBjSTcydTBRd1BUQzFrRzZscHQxRUE1RzhCeW4yWGg0UmhLV1haYW00b21WZWtrR3kydk9kay15eUtDZnFyT3FBZ3VrTg?oc=5","date":"2022-03-23","type":"pipeline","source":"ahajournals.org","summary":"Novel CaMKII-δ Inhibitor Hesperadin Exerts Dual Functions to Ameliorate Cardiac Ischemia/Reperfusion Injury and Inhibit Tumor Growth | Circulation - ahajournals.org","headline":"Novel CaMKII-δ Inhibitor Hesperadin Exerts Dual Functions to Ameliorate Cardiac Ischemia/Reperfusion Injury and Inhibit ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE05d3R6YkdTOUoxZVhuaXZpazBvdGl4LXdnd1RHZGpUcWVoemtrMDlmajB6eEEtekYtNDRzNEtlWVBKYVVVWVM4ei11VkpkRkdzRmVMSFpYM1drbjBjRFJrYlJYc1FTY2p1U1JMWkFZYlNoS00?oc=5","date":"2020-10-06","type":"pipeline","source":"ahajournals.org","summary":"Treatment of Masked Hypertension with a Chinese Herbal Formula | Circulation - ahajournals.org","headline":"Treatment of Masked Hypertension with a Chinese Herbal Formula | Circulation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE0xNjhzQkZGcnF3TGsxY3BzamhqaTBZY3czb19HekptWTJ1MC1zMkdlTVF1UW95NEF4SVVvWVB0V2hzbkFNZk9iaE4yODFDdnlFNnUzVGdsUE02WUNIeUJyOUZWWVRwcFJhd3c2Yg?oc=5","date":"2020-01-17","type":"pipeline","source":"ahajournals.org","summary":"Carotid Intima-Media Thickness and the Risk of First Stroke in Patients With Hypertension - ahajournals.org","headline":"Carotid Intima-Media Thickness and the Risk of First Stroke in Patients With Hypertension","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFByS0tndWFSUlhaVm9QdXU0bmZHQ05mZzdRR1BQVUdjeUJKUXpwNmJJaTRKV1JCQ1ZCYVJxaFNxclYtLTFxOERyXzk2SlF0dUwtYkcxYmxmSC1tenFUMWFR?oc=5","date":"2018-07-30","type":"pipeline","source":"Nature","summary":"A network pharmacology-based approach to analyse potential targets of traditional herbal formulas: An example of Yu Ping Feng decoction - Nature","headline":"A network pharmacology-based approach to analyse potential targets of traditional herbal formulas: An example of Yu Ping","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1fNG9Nd2tHWldOOHJka2xncU9OVzdwQVN1S1lCaGsxVjlIWXJ3LWthdTUzbE9mRHR3b19oMmNpSzdYOUNsTExQVkthUnUzX2tqYTRWeDJRckJKMVp0WDlXc2NrZ09iWXRpR2RYQi11UjdZQ0lFX0JB?oc=5","date":"2017-09-06","type":"pipeline","source":"VCU News","summary":"VCU researchers combat opiate addiction - VCU News","headline":"VCU researchers combat opiate addiction","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}